Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qinghua and blood stasis–removing staged TCM preparations for IgA nephropathy
ChiCTR2400094993Phase 2Recruiting
- Sponsor
- Shuguang Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of losartan, Astragalus Xiaobai, Gubentongluo and Yishen Zhishuang Granules in IgA nephropathy (IgAN) (6 arms), sponsored by Shuguang Hospital. Primary endpoint: 24-hour urinary protein quantification. Started Dec 2024; status: recruiting.
02
Drugs
losartanAstragalus XiaobaiGubentongluoYishen Zhishuang Granules
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2400094993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094993.